Sign In
Last checked at 
Today 07:00
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")
IMC Presentation Statement
29 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, will be presenting to shareholders at 09.00 BST today, Monday 29 June 2026 on the Investor Meet Company platform (see details below). The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO.
The presentation will be brief and cover recent post period events, the investigation and the disclosable information from the FRP Advisory report, before running through the recent HY26 results, post period trading and outlook. The Company will also be stating that the FY26 results will be prepared on a going concern basis.
Presentation details
The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics via the link HERE. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Alyson Levett, Acting ChairRachel Parsonage, Interim CEO | ir@skinbiotix.com
|
Singer Capital Markets (Nominated Adviser & Broker)Alex BondSara HalePatrick Weaver | +44 (0) 020 7496 3000
|
Vigo Consulting Melanie Toyne-Sewell, Rozi Morris | +44 (0) 20 7390 0230 SkinBio@vigoconsulting.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.
SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.
Follow the stocks
